Coming back to the SPIEF’17, our colleagues from Sechenov University signed the cooperation agreement in the scientific and educational field with biotechnical company Biocad. The objective of this cooperation is the development of collaborative educational programs for specialists in clinical trials sphere, also for the establishment of relevant world-class scientific-educational projects.
Biocad chief executive officer Dmitry Morozov says – today’s labor market hasn’t clinical studies specialists, so it is impossible to conduct trials and accomplish necessary tasks on the appropriate level.
Planned investments in the production of medicines in St. Petersburg are estimated at 20 billion rubles in the next 3-5 years. Also, the company will begin construction of its first production facility in Europe in 2018, in the city of Turku (Finland).
Biotechnology, Bioengineering, Bioinformatics, which are relevant for this area, are being conducted by Moscow State Medical University named after Sechenov since 2010, and also the University offers postgraduate professional training programs for pharmacists.